C omposition for preventing or treating sjogren's syndrome comprising PAX3

The present invention appeared to be PAX3 is that identified potential as new therapeutic agents that can effectively treat Sjogren's syndrome, when overexpressed the PAX3 the two Sjogren's syndrome induced animal model of the symptoms of Sjogren's syndrome relief and improvement of inflammatory cytokines produced also shown to be suppressed. Further in vitro experiments and Sjogren patients was analyzed for the onset Sjogren targeting sample PAX3 expression changes, Sjogren's syndrome environment the composition when PAX3 of the present invention as identified that reduce the expression of PAX3 is therapeutic targets for new Sjogren's syndrome I could see that this could be the expression and activity of the promoter and PAX3 PAX3 it was found that the effect can be effective prevention and treatment of Sjogren's syndrome.